Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The implementation of screening for prostate cancer

Prostate Cancer and Prostatic Diseases volume 13, pages 218–227 (2010)Cite this article

Subjects

Abstract

The objective of this study was to determine whether screening for prostate cancer (PC) reduces PC mortality and, if so, whether the required criteria to be introduced as a population-based screening program are satisfied. A literature review was conducted through electronic scientific databases. The screening tests, that is, PSA and digital rectal examination, have limited sensitivity and specificity for detecting PC; screening produces a beneficial stage shift and reduces PC mortality. Nevertheless, PC screening causes a large increase in the cumulative incidence, and the understanding of the economic cost and quality-of-life parameters are limited. PC screening cannot be justified yet in the context of a public health policy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P . Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581–592.

    Article  CAS  PubMed  Google Scholar 

  2. Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH, Schmidlin F et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 2008; 123: 421–429.

    Article  CAS  PubMed  Google Scholar 

  3. SEER. SEER Cancer Statistics Review 1975-200 http://seercancergov/csr/1975_2006/results_merged/topic_lifetime_riskpdf; 2006.

  4. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008; 9: 445–452.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Dixon H, Scully M, Wakefield M, Murphy M . The prostate cancer screening debate: public reaction to medical controversy in the media. Public Underst Sci 2009; 18: 115–128.

    Article  PubMed  Google Scholar 

  6. Habbema JD, van Oortmarssen GJ, van der Maas PJ . Mass screening for cancer: the interpretation of findings and the prediction of effects on morbidity and mortality. Clin Lab Med 1982; 2: 627–638.

    Article  CAS  PubMed  Google Scholar 

  7. Pienta KJ . Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later. Urology 2009; 73 (5 Suppl): S11–S20.

    Article  PubMed  Google Scholar 

  8. Wilson JM, Jungner YG . (Principles and practice of mass screening for disease). Bol Oficina Sanit Panam 1968; 65: 281–393.

    CAS  PubMed  Google Scholar 

  9. Luciano S, Berman N . Population cancer screening in Canada: strategic and priorities. Canadian Strategy for Cancer Control 2000; 21: 1–11.

    Google Scholar 

  10. Lindegren ML, Kobrynski L, Rasmussen SA, Moore CA, Grosse SD, Vanderford ML et al. Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Recomm Rep 2004; 53 (RR-1): 1–29.

    PubMed  Google Scholar 

  11. Andermann A, Blancquaert I, Beauchamp S, Dery V . Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008; 86: 317–319.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Davidson PGJ . Should mass screening for prostate cancer be introduced at the national level?. WHO Regional Office for Europe: Copenhagen. Available at http://www.eurowhoint/Document/E82958pdf; 2004.

  13. Union E. Council recommendation on cancer screening. Official J Eur Union 2003; L 327/34.

  14. Committee UNS. Second report of the UK National Screening Committee. Available at www.nscnhsuk2004; 2004.

  15. Regelgeving W-e . Wet op het bevolkingsonderzoek. http://wettenoverheidnl; 2009.

  16. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–1161.

    Article  CAS  PubMed  Google Scholar 

  17. Lilja H . Biology of prostate-specific antigen. Urology 2003; 62 (5 Suppl 1): 27–33.

    Article  PubMed  Google Scholar 

  18. Schroder FH, Denis LJ, Roobol M, Nelen V, Auvinen A, Tammela T et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003; 92 (Suppl 2): 1–13.

    Article  PubMed  Google Scholar 

  19. Sindhwani P, Wilson CM . Prostatitis and serum prostate-specific antigen. Curr Urol Rep 2005; 6: 307–312.

    Article  PubMed  Google Scholar 

  20. Rao AR, Motiwala HG, Karim OM . The discovery of prostate-specific antigen. BJU Int 2008; 101: 5–10.

    Article  CAS  PubMed  Google Scholar 

  21. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294: 66–70.

    Article  CAS  PubMed  Google Scholar 

  22. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ⩽4.0 ng per milliliter. N Engl J Med 2004; 350: 2239–2246.

    Article  CAS  PubMed  Google Scholar 

  23. Thompson IM, Ankerst DP . Prostate-specific antigen in the early detection of prostate cancer. CMAJ 2007; 176: 1853–1858.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Schroder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 2008; 53: 468–477.

    Article  PubMed  Google Scholar 

  25. Postma R, Schroder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)—Section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007; 52: 89–97.

    Article  PubMed  Google Scholar 

  26. Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y et al. Prostate-specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002; 60: 469–473; discussion 473–64.

    Article  PubMed  Google Scholar 

  27. Gohagan JK, Prorok PC, Hayes RB, Kramer BS . The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000; 21 (6 Suppl): 251S–272S.

    Article  CAS  PubMed  Google Scholar 

  28. Loeb S, Catalona WJ . What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels? Nat Clin Pract Urol 2009; 6: 68–69.

    Article  PubMed  Google Scholar 

  29. Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA . Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 1996; 47: 863–869.

    Article  CAS  PubMed  Google Scholar 

  30. Schroder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998; 90: 1817–1823.

    Article  CAS  PubMed  Google Scholar 

  31. Yamamoto T, Ito K, Ohi M, Kubota Y, Suzuki K, Fukabori Y et al. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 ng/ml or less. Urology 2001; 58: 994–998.

    Article  CAS  PubMed  Google Scholar 

  32. Bozeman CB, Carver BS, Caldito G, Venable DD, Eastham JA . Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/ml. Urology 2005; 66: 803–807.

    Article  PubMed  Google Scholar 

  33. Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005; 97: 433–438.

    Article  PubMed  Google Scholar 

  34. Borden Jr LS, Wright JL, Kim J, Latchamsetty K, Porter CR . An abnormal digital rectal examination is an independent predictor of Gleason ⩾7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men. BJU Int 2007; 99: 559–563.

    Article  PubMed  Google Scholar 

  35. Ghavamian R, Blute ML, Bergstralh EJ, Slezak J, Zincke H . Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology 1999; 54: 105–110.

    Article  CAS  PubMed  Google Scholar 

  36. Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ . Characteristics of prostate cancer detected by digital rectal examination only. Urology 2007; 70: 1117–1120.

    Article  PubMed  Google Scholar 

  37. Gosselaar C, Roobol MJ, Roemeling S, de Vries SH, Cruijsen-Koeter I, van der Kwast TH et al. Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Prostate 2006; 66: 625–631.

    Article  PubMed  Google Scholar 

  38. Rodriguez LV, Terris MK . Risks and complications of transrectal ultrasound. Curr Opin Urol 2000; 10: 111–116.

    Article  CAS  PubMed  Google Scholar 

  39. Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001; 166: 856–860.

    Article  CAS  PubMed  Google Scholar 

  40. Villers A, Malavaud B, Rebillard X, Bataille V, Iborra F . ERSPC: features and preliminary results of France. BJU Int 2003; 92 (Suppl 2): 27–29.

    Article  PubMed  Google Scholar 

  41. Berenguer A, Lujan M, Paez A, Santonja C, Pascual T . The Spanish contribution to the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003; 92 (Suppl 2): 33–38.

    Article  PubMed  Google Scholar 

  42. Hugosson J, Aus G, Bergdahl S, Fernlund P, Frosing R, Lodding P et al. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. BJU Int 2003; 92 (Suppl 2): 39–43.

    Article  PubMed  Google Scholar 

  43. Kwiatkowski M, Huber A, Stamm B, Lehmann K, Wernli M, Hafeli A et al. Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland. BJU Int 2003; 92 (Suppl 2): 44–47.

    Article  PubMed  Google Scholar 

  44. Finne P, Stenman UH, Maattanen L, Makinen T, Tammela TL, Martikainen P et al. The Finnish trial of prostate cancer screening: where are we now? BJU Int 2003; 92 (Suppl 2): 22–26.

    Article  PubMed  Google Scholar 

  45. Ciatto S, Gervasi G, Frullini P, Zendron P, Zappa M . Specific features of the Italian section of the ERSPC. BJU Int 2003; 92 (Suppl 2): 30–32.

    Article  PubMed  Google Scholar 

  46. Roobol MJ, Schroder FH . European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int 2003; 92 (Suppl 2): 117–122.

    Article  PubMed  Google Scholar 

  47. Andriole GL, Grubb III RL, Buys SS, Chia D, Church TR, Fouad MN et al. Mortality results from a Randomized Prostate-Cancer Screening Trial. N Engl J Med 2009; 360: 1310–1319.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320–1328.

    Article  PubMed  Google Scholar 

  49. van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. J Urol 2005; 174: 121–125.

    Article  PubMed  Google Scholar 

  50. Grubb III RL, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP et al. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008; 102: 1524–1530.

    Article  PubMed  Google Scholar 

  51. van der Cruijsen-Koeter IW, Roobol MJ, Wildhagen MF, van der Kwast TH, Kirkels WJ, Schroder FH . Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. Urology 2006; 68: 615–620.

    Article  PubMed  Google Scholar 

  52. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. N Engl J Med 2009; 360: 1320–1328.

    Article  PubMed  Google Scholar 

  53. Wolters T, Roobol MJ, Steyerberg EW, van den Bergh RC, Bangma CH, Hugosson J et al. The effect of study arm on prostate cancer treatment in a large screening trial (ERSPC). Int J Cancer 2010; 126: 2387–2393.

    CAS  PubMed  Google Scholar 

  54. Roobol MJ, Kerkhof M, Schroder FH, Cuzick J, Sasieni P, Hakama M et al. Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009; 56: 584–591.

    Article  PubMed  Google Scholar 

  55. van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH et al. Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit. Eur J Cancer 2010; 46: 377–383.

    Article  PubMed  Google Scholar 

  56. Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schroder FH et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 2003; 105: 394–399.

    Article  CAS  PubMed  Google Scholar 

  57. Ciatto S, Zappa M, Villers A, Paez A, Otto SJ, Auvinen A . Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU Int 2003; 92 (Suppl 2): 97–100.

    Article  PubMed  Google Scholar 

  58. White WM, Sadetsky N, Waters WB, Carroll PR, Litwin MS . Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database. J Urol 2008; 180: 2409–2413; discussion 2414.

    Article  PubMed  Google Scholar 

  59. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1250–1261.

    Article  CAS  PubMed  Google Scholar 

  60. Gotzsche PC, Nielsen M . Screening for breast cancer with mammography. Cochrane Database Syst Rev 2006; issue no. (4).

  61. Poplack SP, Tosteson AN, Grove MR, Wells WA, Carney PA . Mammography in 53,803 women from the New Hampshire mammography network. Radiology 2000; 217: 832–840.

    Article  CAS  PubMed  Google Scholar 

  62. Vejborg I, Olsen AH, Jensen MB, Rank F, Tange UB, Lynge E . Early outcome of mammography screening in Copenhagen 1991-99. J Med Screen 2002; 9: 115–119.

    Article  CAS  PubMed  Google Scholar 

  63. Wang H, Karesen R, Hervik A, Thoresen SO . Mammography screening in Norway: results from the first screening round in four counties and cost-effectiveness of a modeled nationwide screening. Cancer Causes Control 2001; 12: 39–45.

    Article  CAS  PubMed  Google Scholar 

  64. Institute NC. Inventory of colorectal cancer screening activities in ICSN countries, June 2006. Available at http://appliedresearchcancergov/icsn/colorectal/screeninghtml; 2006.

  65. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E . Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007; issue no. (1).

  66. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L . Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103: 1541–1549.

    Article  PubMed  Google Scholar 

  67. Grazzini G, Castiglione G, Ciabattoni C, Franceschini F, Giorgi D, Gozzi S et al. Colorectal cancer screening programme by faecal occult blood test in Tuscany: first round results. Eur J Cancer Prev 2004; 13: 19–26.

    Article  CAS  PubMed  Google Scholar 

  68. Pignone M, Saha S, Hoerger T, Mandelblatt J . Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137: 96–104.

    Article  PubMed  Google Scholar 

  69. Manser RL, Irving LB, Stone C, Byrnes G, Abramson M, Campbell D . Screening for lung cancer. Cochrane Database Syst Rev 2004; issue no. (1).

  70. Gohagan J, Marcus P, Fagerstrom R, Pinsky P, Kramer B, Prorok P . Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest 2004; 126: 114–121.

    Article  PubMed  Google Scholar 

  71. Laara E, Day NE, Hakama M . Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987; 1: 1247–1249.

    Article  CAS  PubMed  Google Scholar 

  72. Sankaranarayanan R, Nene BM, Dinshaw KA, Mahe C, Jayant K, Shastri SS et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer 2005; 116: 617–623.

    Article  CAS  PubMed  Google Scholar 

  73. Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N . Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004; 8: iii 1–78.

    Article  Google Scholar 

  74. Cancer research UK. Prostate cancer. UK Incidence Statistics. Cancer Research: UK, 2009.

  75. Integraal Kankercentrum Rotterdam. IKCnet. http://www.ikcnetnl/IKR/indexphp; 2009.

  76. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH . et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868–878.

    Article  PubMed  Google Scholar 

  77. Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RC, Bangma CH et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010; 57: 79–85.

    Article  PubMed  Google Scholar 

  78. Roobol MJ, Schroder FH, Crawford ED, Freedland SJ, Sartor AO, Fleshner N et al. A framework for the identification of men at increased risk for prostate cancer. J Urol 2009; 182: 2112–2120.

    Article  PubMed  Google Scholar 

  79. Crawford ED, Andriole GL, Marberger M, Rittmaster RS . Reduction in the risk of prostate cancer: future directions after the prostate cancer prevention trial. Urology 2010; 75: 502–509.

    Article  PubMed  Google Scholar 

  80. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–224.

    Article  CAS  PubMed  Google Scholar 

  81. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192–1202.

    Article  CAS  PubMed  Google Scholar 

  82. Thompson IM, Tangen CM, Parnes HL, Lippman SM, Coltman Jr CA . Does the level of prostate cancer risk affect cancer prevention with finasteride? Urology 2008; 71: 854–857.

    Article  PubMed  Google Scholar 

  83. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007; 177: 1749–1752.

    Article  CAS  PubMed  Google Scholar 

  84. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98: 1128–1133.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are working for the ERSPC Netherlands, which is supported by grants from the Dutch Cancer Society (KWF 94-869, 98-1657, 2002-277, 2006-3518), The Netherlands Organization for Health Research and Development (002822820, 22000106, 50-50110-98-311), Sixth Framework Program of the EU: P-Mark: LSHC-CT-2004-503011, Beckman Coulter Hybritech Inc. and of Europe against Cancer (SOC 95 35109, SOC 96 201869 05F02, SOC 97 201329, SOC 98 32241).

Author information

Authors and Affiliations

  1. Department of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands

    P J van Leeuwen, H A van Vugt & C H Bangma

Authors
  1. P J van Leeuwen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H A van Vugt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C H Bangma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P J van Leeuwen.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Leeuwen, P., van Vugt, H. & Bangma, C. The implementation of screening for prostate cancer. Prostate Cancer Prostatic Dis 13, 218–227 (2010). https://doi.org/10.1038/pcan.2010.14

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2010.14

Keywords

This article is cited by

Search

Advanced search

Quick links